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Foamy viruses are a group of retroviruses that ubiquitously infect primates and some other 
mammals. Every examined primate except humans is infected with a simian foamy virus (SFV), and 
these viruses have co-speciated with their hosts for millions of years (Switzer, et al.,  2005). SFV is 
latent in most infected monkey cells, including blood cells, and only replicates in oral mucosa. 
Infectious virus is thought to be secreted into the saliva from the oral mucosa. Humans in contact 
with monkeys are frequently infected with SFV through contact with monkey saliva; however, the 
virus does not replicate efficiently in humans and there has been no documented case human-to-
human SFV transmission. Thus far, there do not appear to be pathogenic consequences of SFV 
infection for either monkeys or humans.  
It is currently unclear why SFV does not efficiently infect humans. To understand this difference in 
host susceptibility, the laboratories of Lisa Jones-Engel (University of Washington), Maxine L. Linial 
(Basic Sciences Division) with their longstanding collaboration exploring the epidemiology and 
virology of SFV, teamed up with Erick Matsen’s laboratory (Public Health Sciences Division), along 
with an international team of collaborators, to develop a Bayesian approach to identify APOBEC-
mediated hypermutation in SFV DNA. In a recent paper published in PLoS Computational Biology, 
Matsen, et al. demonstrate that human APOBEC3G mutates SFV and likely represents a barrier to 
cross-species transmission. 
APOBEC3s are a family of cytidine deaminases that generate an excess of G to A mutations 
(hypermutation) in the viral genome during reverse transcription. Hypermutation results in nonsense 
and missense mutations that can prevent further viral replication by disrupting viral proteins. 
Individual APOBECs act on different nucleotide contexts. For example, APOBEC3G induces 
mutations in a GG dinucleotide context. Traditionally, Fisher’s exact test has been used to identify 
signatures of APOBEC3-related hypermutation. However, this statistical test is inaccurate in 
situations with modest rates of hypermutation, as is the case with APOBEC3. To address this and 
other shortcomings with the Fisher’s exact test, Matsen, et al. developed a Bayesian approach to 
more accurately quantify the rate of mutation within a particular APOBEC3 context relative to the  
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rate of mutation outside this context. This approach also provides a measure of the effect size, e.g. if 
APOBEC3 can act in a given context what is the probability that it will mutate the sequence. Overall, 
this Bayesian method is more accurate than currently used methods to quantify hypermutation in a 
given sequence. 
To determine whether APOBEC3 inhibits SFV replication in humans, Matsen et al. assayed the SFV 
gag gene, which encodes the viral structural proteins and is the most variable gene in SFV, for signs 
of hypermutation. In gag sequences derived from either free-ranging macaques or from the blood of 
zoonotically infected humans the team found that human-derived SFV sequences had significantly 
higher levels of hypermutation comparing either blood samples from the two species (p = 1.7×10-4) 
or comparing human blood samples to macaque buccal (p = 4.3×10-4). Furthermore, hypermutated 
human sequences were significantly more likely to contain stop codons in the gag coding region (p = 
6.5×10-13) that would prevent viral replication.  Hypermutation in the human samples was primarily 
associated with either GG or GR dinucleotides, while the macaque samples were most frequently in 
GA or GM dinucleotide contexts, suggesting that different APOBEC3 family members may be active 
in the different species. Taken together, these data suggest that APOBEC3G presents a barrier to 
the cross-species transmission of SFV to humans. 
Matsen et al. have developed a new, powerful tool to more sensitively identify signatures of 
hypermutation. In the current study, this Bayesian approach demonstrated that human-derived SFV 
sequences has undergone significant APOBEC3-mediated hypermutation, providing indirect 
evidence that the virus does go through at least one round of replication in humans. Going forward, 
"another interesting question is whether the non-structural SFV protein Bet is involved in protecting 
the virus from APOBEC3-mediated hypermutation," said Dr. Maxine Linial. 
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Image from Matsen, et al., 2014. 
The Maximum A Posteriori relative probability of hypermutation in SFV sequences derived from 
monkeys (green) or humans (blue) demonstrating that human sequences are shifted to the right and 
therefore more likely to be hypermutated (top). The most common dinucleotide context for each 
sample (middle) and presence of non-sense mutations (bottom) are also shown for each sample. 
 
